Clin Endosc.  2013 Jan;46(1):30-37. 10.5946/ce.2013.46.1.30.

Photodynamic Therapy for Barrett's Esophagus and Esophageal Carcinoma

• Qumseya BJ
• David W
• Wolfsen HC

• KMID: 1792637
• DOI: http://doi.org/10.5946/ce.2013.46.1.30

Abstract

This paper reviews the use of photodynamic therapy (PDT) in patients with Barrett's esophagus and esophageal carcinoma. We describe the history of PDT, mechanics, photosensitizers for PDT in patients with esophageal disease. Finally, we discuss its utility and limitations in this setting.

Keyword

Barrett esophagus; Esophageal neoplasms; Dihematoporphyrin ether; Aminolevulinic acid; Ablation therapy

MeSH Terms

Aminolevulinic Acid
Barrett Esophagus
Dihematoporphyrin Ether
Esophageal Diseases
Esophageal Neoplasms
Humans
Mechanics
Photochemotherapy
Photosensitizing Agents
Triazenes
Aminolevulinic Acid
Dihematoporphyrin Ether
Photosensitizing Agents
Triazenes

Reference

1. Hahn SM, Putt ME, Metz J, et al. Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin Cancer Res. 2006; 12:5464–5470. PMID: 17000681.

2. McCaughan JS Jr, Ellison EC, Guy JT, et al. Photodynamic therapy for esophageal malignancy: a prospective twelve-year study. Ann Thorac Surg. 1996; 62:1005–1009. PMID: 8823080.

3. Litle VR, Luketich JD, Christie NA, et al. Photodynamic therapy as palliation for esophageal cancer: experience in 215 patients. Ann Thorac Surg. 2003; 76:1687–1692. PMID: 14602313.

4. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005; 62:488–498. PMID: 16185958.

5. Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc. 2007; 66:460–468. PMID: 17643436.

6. Wolfsen HC. Endoluminal therapy for Barrett's esophagus. Gastrointest Endosc Clin N Am. 2007; 17:59–82. PMID: 17397777.

7. Wolfsen HC. Present status of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. J Clin Gastroenterol. 2005; 39:189–202. PMID: 15718860.

8. Wolfsen HC. Carpe luz-seize the light: endoprevention of esophageal adenocarcinoma when using photodynamic therapy with porfimer sodium. Gastrointest Endosc. 2005; 62:499–503. PMID: 16185960.

9. Wolfsen HC. Endoprevention of esophageal cancer: endoscopic ablation of Barrett's metaplasia and dysplasia. Expert Rev Med Devices. 2005; 2:713–723. PMID: 16293098.

10. Prosst RL, Wolfsen HC, Gahlen J. Photodynamic therapy for esophageal diseases: a clinical update. Endoscopy. 2003; 35:1059–1068. PMID: 14648421.

11. Wang KK. Current status of photodynamic therapy of Barrett's esophagus. Gastrointest Endosc. 1999; 49(3 Pt 2):S20–S23. PMID: 10049443.

12. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc. 2003; 58:183–188. PMID: 12872083.

13. Sampliner RE. Prevention of adenocarcinoma by reversing Barrett's esophagus with mucosal ablation. World J Surg. 2003; 27:1026–1029. PMID: 12917762.

14. Winship MJ, Wang S, Chen JC, Keltner L, Christophersen JS. Treatment of colorectal liver metastases using talaporfin sodium and intratumoral placement of LEDs [abstract]. J Clin Oncol. 2005; 23(16 Suppl):3663. PMID: 15738543.

15. Konan-Kouakou YN, Boch R, Gurny R, Allémann E. In vitro and in vivo activities of verteporfin-loaded nanoparticles. J Control Release. 2005; 103:83–91. PMID: 15710502.

16. Dougherty TJ. An update on photodynamic therapy applications. J Clin Laser Med Surg. 2002; 20:3–7. PMID: 11902352.

17. Allison SP, Lobo DN. Fluid and electrolytes in the elderly. Curr Opin Clin Nutr Metab Care. 2004; 7:27–33. PMID: 15090900.

18. Qiang YG, Zhang XP, Li J, Huang Z. Photodynamic therapy for malignant and non-malignant diseases: clinical investigation and application. Chin Med J (Engl). 2006; 119:845–857. PMID: 16732988.

19. Pereira SP, Ayaru L, Ackroyd R, et al. The pharmacokinetics and safety of porfimer after repeated administration 30-45 days apart to patients undergoing photodynamic therapy. Aliment Pharmacol Ther. 2010; 32:821–827. PMID: 20629974.

20. Yano S, Hirohara S, Obata M, et al. Current states and future views in photodynamic therapy. J Photochem Photobiol C. 2011; 12:46–67.

21. Perry Y, Epperly MW, Fernando HC, et al. Photodynamic therapy induced esophageal stricture: an animal model: from mouse to pig. J Surg Res. 2005; 123:67–74. PMID: 15652952.

22. Cramers P, Ruevekamp M, Oppelaar H, Dalesio O, Baas P, Stewart FA. Foscan uptake and tissue distribution in relation to photodynamic efficacy. Br J Cancer. 2003; 88:283–290. PMID: 12610515.

23. Wagnieres G, Hadjur C, Grosjean P, et al. Clinical evaluation of the cutaneous phototoxicity of 5,10,15,20-tetra(m-hydroxyphenyl)chlorin. Photochem Photobiol. 1998; 68:382–387. PMID: 9747593.

24. Barr H, Kendall C, Stone N. Photodynamic therapy for esophageal cancer: a useful and realistic option. Technol Cancer Res Treat. 2003; 2:65–76. PMID: 12625755.

25. Bown SG, Rogowska AZ. New photosensitizers for photodynamic therapy in gastroenterology. Can J Gastroenterol. 1999; 13:389–392. PMID: 10377468.

26. Paskowitz DM, Donohue-Rolfe KM, Yang H, et al. Neurotrophic factors minimize the retinal toxicity of verteporfin photodynamic therapy. Invest Ophthalmol Vis Sci. 2007; 48:430–437. PMID: 17197564.

27. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001; 32:368–378. PMID: 11331953.

28. Zaninotto G, Minnei F, Guirroli E, et al. The Veneto region's Barrett's oesophagus registry: aims, methods, preliminary results. Dig Liver Dis. 2007; 39:18–25. PMID: 17141593.

29. Falk GW. Barrett's esophagus. Gastroenterology. 2002; 122:1569–1591. PMID: 12016424.

30. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998; 83:2049–2053. PMID: 9827707.

31. Tokar JL, Haluszka O, Weinberg DS. Endoscopic therapy of dysplasia and early-stage cancers of the esophagus. Semin Radiat Oncol. 2007; 17:10–21. PMID: 17185193.

32. Andrejevic Blant S, Grosjean P, Ballini JP, et al. Localization of tetra(m-hydroxyphenyl) chlorin (Foscan) in human healthy tissues and squamous cell carcinomas of the upper aero-digestive tract, the esophagus and the bronchi: a fluorescence microscopy study. J Photochem Photobiol B. 2001; 61:1–9. PMID: 11485842.

33. Ackroyd R, Kelty C, Brown N, Reed M. The history of photodetection and photodynamic therapy. Photochem Photobiol. 2001; 74:656–669. PMID: 11723793.

34. Dunn JM, Mackenzie GD, Banks MR. A randomised controlled trial of ALA vs. Photofrin photodynamic therapy for high-grade dysplasia arising in Barrett's oesophagus. Lasers Med Sci;Epub 2012 Jun 15. DOI: http://dx.doi.org/10.1007/s10103-012-1132-1.

35. Overholt B, Panjehpour M, Tefftellar E, Rose M. Photodynamic therapy for treatment of early adenocarcinoma in Barrett's esophagus. Gastrointest Endosc. 1993; 39:73–76. PMID: 8454152.

36. Wang KK, Kim JY. Photodynamic therapy in Barrett's esophagus. Gastrointest Endosc Clin N Am. 2003; 13:483–489. PMID: 14629104.

37. Wolfsen HC, Woodward TA, Raimondo M. Photodynamic therapy for dysplastic Barrett esophagus and early esophageal adenocarcinoma. Mayo Clin Proc. 2002; 77:1176–1181. PMID: 12440553.

38. Wolfsen HC, Hemminger LL, Wallace MB, Devault KR. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer. Aliment Pharmacol Ther. 2004; 20:1125–1131. PMID: 15569115.

39. Wang KK, Wong Kee, Buttar N, Papenfuss S, Lutzke L. Barrett's esophagus after photodynamic therapy: risk of cancer development during long term follow-up [abstract]. Gastroenterology. 2004; 126(5 Suppl 2):A50.

40. Wolfsen HC, Hemminger LL. Photodynamic therapy for dysplastic Barrett's esophagus and mucosal adenocarcinoma [abstract]. Gastrointest Endosc. 2004; 59:AB251.

41. Panjehpour M, Overholt BF, Haydek JM, Lee SG. Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation. Am J Gastroenterol. 2000; 95:2177–2184. PMID: 11007214.

42. Panjehpour M, Overholt BF, Phan MN, Haydek JM. Optimization of light dosimetry for photodynamic therapy of Barrett's esophagus: efficacy vs. incidence of stricture after treatment. Gastrointest Endosc. 2005; 61:13–18. PMID: 15672050.

43. Peng Q, Warloe T, Moan J, et al. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts. Cancer Res. 2001; 61:5824–5832. PMID: 11479222.

44. Peng Q, Warloe T, Berg K, et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer. 1997; 79:2282–2308. PMID: 9191516.

45. Godal A, Nilsen NO, Klaveness J, Branden JE, Nesland JM, Peng Q. New derivatives of 5-aminolevulinic acid for photodynamic therapy: chemical synthesis and porphyrin production in in vitro and in vivo biological systems. J Environ Pathol Toxicol Oncol. 2006; 25:109–126. PMID: 16566712.

46. Bedwell J, MacRobert AJ, Phillips D, Bown SG. Fluorescence distribution and photodynamic effect of ALA-induced PP IX in the DMH rat colonic tumour model. Br J Cancer. 1992; 65:818–824. PMID: 1616853.

47. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B. 1992; 14:275–292. PMID: 1403373.

48. Peng Q, Berg K, Moan J, Kongshaug M, Nesland JM. 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol. 1997; 65:235–251. PMID: 9066303.

49. Webber J, Kessel D, Fromm D. Side effects and photosensitization of human tissues after aminolevulinic acid. J Surg Res. 1997; 68:31–37. PMID: 9126192.

50. Gossner L, May A, Sroka R, Ell C. A new long-range through-the-scope balloon applicator for photodynamic therapy in the esophagus and cardia. Endoscopy. 1999; 31:370–376. PMID: 10433046.

51. Gossner L, Stolte M, Sroka R, et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology. 1998; 114:448–455. PMID: 9496934.

52. Barr H, Shepherd NA, Dix A, Roberts DJ, Tan WC, Krasner N. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet. 1996; 348:584–585. PMID: 8774572.

53. Orth K, Stanescu A, Rück A, Russ D, Beger HG. Photodynamic ablation and argon-plasma coagulation of premalignant and early-stage malignant lesions of the oesophagus: an alternative to surgery? Chirurg. 1999; 70:431–438. PMID: 10354840.

54. Ackroyd R, Brown NJ, Davis MF, et al. Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial. Gut. 2000; 47:612–617. PMID: 11034574.

55. Ackroyd R, Brown NJ, Davis MF, Stephenson TJ, Stoddard CJ, Reed MW. Aminolevulinic acid-induced photodynamic therapy: safe and effective ablation of dysplasia in Barrett's esophagus. Dis Esophagus. 2000; 13:18–22. PMID: 11005326.

56. Pech O, Gossner L, May AD, Stolte M, Ell C. Long term results of PDT for early neoplasia in Barrett's esophagus [abstract]. Gastrointest Endosc. 2004; 59:P257.

57. Guelrud M, Herrera I, Essenfeld H, Castro J. Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc. 2001; 53:559–565. PMID: 11323579.

58. Behrens A, May A, Gossner L, et al. Curative treatment for high-grade intraepithelial neoplasia in Barrett's esophagus. Endoscopy. 2005; 37:999–1005. PMID: 16189774.

59. May A, Gossner L, Pech O, et al. Intraepithelial high-grade neoplasia and early adenocarcinoma in short-segment Barrett's esophagus (SSBE): curative treatment using local endoscopic treatment techniques. Endoscopy. 2002; 34:604–610. PMID: 12173079.

60. Sylantiev C, Schoenfeld N, Mamet R, Groozman GB, Drory VE. Acute neuropathy mimicking porphyria induced by aminolevulinic acid during photodynamic therapy. Muscle Nerve. 2005; 31:390–393. PMID: 15490483.

61. Ortner MA, Zumbusch K, Liebetruth J, et al. Is topical delta-aminolevulinic acid adequate for photodynamic therapy in Barrett's esophagus? A pilot study. Endoscopy. 2002; 34:611–616. PMID: 12173080.

62. Ragunath K, Krasner N, Raman VS, Haqqani MT, Phillips CJ, Cheung I. Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness. Scand J Gastroenterol. 2005; 40:750–758. PMID: 16118910.

63. Kelty CJ, Ackroyd R, Brown NJ, Brown SB, Reed MW. Comparison of high- vs low-dose 5-aminolevulinic acid for photodynamic therapy of Barrett's esophagus. Surg Endosc. 2004; 18:452–458. PMID: 14752635.

64. Kelty CJ, Ackroyd R, Brown NJ, Stephenson TJ, Stoddard CJ, Reed MW. Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther. 2004; 20:1289–1296. PMID: 15606390.

65. Andrejevic-Blant S, Hadjur C, Ballini JP, et al. Photodynamic therapy of early squamous cell carcinoma with tetra(m-hydroxyphenyl)chlorin: optimal drug-light interval. Br J Cancer. 1997; 76:1021–1028. PMID: 9376261.

66. van den Bergh H. On the evolution of some endoscopic light delivery systems for photodynamic therapy. Endoscopy. 1998; 30:392–407. PMID: 9689515.

67. Overholt BF, Panjehpour M, DeNovo RC, Peterson MG, Jenkins C. Balloon photodynamic therapy of esophageal cancer: effect of increasing balloon size. Lasers Surg Med. 1996; 18:248–252. PMID: 8778519.

68. Stepinac T, Grosjean P, Woodtli A, Monnier P, van den Bergh H, Wagnieres G. Optimization of the diameter of a radial irradiation device for photodynamic therapy in the esophagus. Endoscopy. 2002; 34:411–415. PMID: 11972275.

69. Braichotte DR, Savary JF, Monnier P, van den Bergh HE. Optimizing light dosimetry in photodynamic therapy of early stage carcinomas of the esophagus using fluorescence spectroscopy. Lasers Surg Med. 1996; 19:340–346. PMID: 8923430.

70. Zellweger M, Grosjean P, Monnier P, van den Bergh H, Wagnières G. Stability of the fluorescence measurement of Foscan in the normal human oral cavity as an indicator of its content in early cancers of the esophagus and the bronchi. Photochem Photobiol. 1999; 69:605–610. PMID: 10333768.

71. Standish BA, Yang VX, Munce NR, et al. Doppler optical coherence tomography monitoring of microvascular tissue response during photodynamic therapy in an animal model of Barrett's esophagus. Gastrointest Endosc. 2007; 66:326–333. PMID: 17643708.

72. Boere IA, Robinson DJ, de Bruijn HS, et al. Monitoring in situ dosimetry and protoporphyrin IX fluorescence photobleaching in the normal rat esophagus during 5-aminolevulinic acid photodynamic therapy. Photochem Photobiol. 2003; 78:271–277. PMID: 14556314.

73. Cheung R, Solonenko M, Busch TM, et al. Correlation of in vivo photosensitizer fluorescence and photodynamic-therapy-induced depth of necrosis in a murine tumor model. J Biomed Opt. 2003; 8:248–252. PMID: 12683850.

74. Radu A, Conde R, Fontolliet C, Wagnieres G, Van den Bergh H, Monnier P. Mucosal ablation with photodynamic therapy in the esophagus: optimization of light dosimetry in the sheep model. Gastrointest Endosc. 2003; 57:897–905. PMID: 12776039.

75. Lindenmann J, Matzi V, Neuboeck N, et al. Individualized, multimodal palliative treatment of inoperable esophageal cancer: clinical impact of photodynamic therapy resulting in prolonged survival. Lasers Surg Med. 2012; 44:189–198. PMID: 22334351.

76. Namasivayam V, Wang KK, Prasad GA. Endoscopic mucosal resection in the management of esophageal neoplasia: current status and future directions. Clin Gastroenterol Hepatol. 2010; 8:743–754. PMID: 20541628.

77. Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology. 2000; 118:670–677. PMID: 10734018.

78. Pech O, Bollschweiler E, Manner H, Leers J, Ell C, Hölscher AH. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann Surg. 2011; 254:67–72. PMID: 21532466.

79. Moss A, Bourke MJ, Hourigan LF, et al. Endoscopic resection for Barrett's high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit. Am J Gastroenterol. 2010; 105:1276–1283. PMID: 20179694.

80. Larghi A, Lightdale CJ, Ross AS, et al. Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma. Endoscopy. 2007; 39:1086–1091. PMID: 17701854.

81. Satodate H, Inoue H, Yoshida T, et al. Circumferential EMR of carcinoma arising in Barrett's esophagus: case report. Gastrointest Endosc. 2003; 58:288–292. PMID: 12872107.

82. Chung A, Bourke MJ, Hourigan LF, et al. Complete Barrett's excision by stepwise endoscopic resection in short-segment disease: long term outcomes and predictors of stricture. Endoscopy. 2011; 43:1025–1032. PMID: 22068701.

83. Chennat J, Konda VJ, Ross AS, et al. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma: an American single-center experience. Am J Gastroenterol. 2009; 104:2684–2692. PMID: 19690526.

84. Peters FP, Krishnadath KK, Rygiel AM, et al. Stepwise radical endoscopic resection of the complete Barrett's esophagus with early neoplasia successfully eradicates pre-existing genetic abnormalities. Am J Gastroenterol. 2007; 102:1853–1861. PMID: 17509033.

85. Ell C, May A, Pech O, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc. 2007; 65:3–10. PMID: 17185072.

86. Sampliner RE. Endoscopic therapy for Barrett's esophagus. Clin Gastroenterol Hepatol. 2009; 7:716–720. PMID: 19306943.

87. Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology. 2011; 141:460–468. PMID: 21679712.

88. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy. 2010; 42:781–789. PMID: 20857372.

89. Lyday WD, Corbett FS, Kuperman DA, et al. Radiofrequency ablation of Barrett's esophagus: outcomes of 429 patients from a multicenter community practice registry. Endoscopy. 2010; 42:272–278. PMID: 20146164.